Literature DB >> 7827817

The management of bilateral ureteric obstruction and renal failure in advanced prostate cancer.

A B Paul1, C Love, G D Chisholm.   

Abstract

OBJECTIVES: To investigate the effect of upper tract decompression on the prognosis of uraemia secondary to bilateral ureteric obstruction in prostate cancer, with particular reference to the hormone dependency of the tumour. PATIENTS AND METHODS: Prospectively collected data, over the period 1978-1993, were selected from the departmental database and from hospital case code data. Inclusion criteria were: blood urea > or = 15 mM, radiological evidence of bilateral ureteric obstruction, a histological diagnosis of prostate cancer, and the exclusion of out-flow tract obstruction. Of the 820 patients recorded in the departmental database, 27 (3.3%) fulfilled the criteria. Thirty-six patients were identified in total. Statistical analysis was by the Mann-Whitney non-parametric test.
RESULTS: Of the 36 patients with bilateral ureteric obstruction and renal failure, in those in whom androgen depletion had been undertaken after ureteric obstruction (i.e. androgen depletion was a treatment option), the mean survival was 646 days (n = 12, SD = 786). Among these patients upper tract decompression improved survival and reduced the amount of time patients spent in hospital. In those in whom androgen depletion had been carried out before obstruction (i.e. the tumour had escaped from hormonal control), survival was significantly worse (80 days, n = 24, SD = 86.8, P < 0.01). In this group the use of decompression improved survival little. Percutaneous nephrostomy was the commonest means of decompression (nephrostomy, 9; stent, 5; ureteroneocystostomy, 2). DISCUSSION: In patients for whom hormonal therapy remains an option, upper tract decompression offers a worthwhile improvement in terms of increased survival and reduced in-patient time. However, if ureteric obstruction is diagnosed after hormone manipulation has been used, upper tract decompression has little effect on survival and should only be used in exceptional circumstances.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7827817     DOI: 10.1111/j.1464-410x.1994.tb09198.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  8 in total

1.  Long-term stenting for benign ureteric disease.

Authors:  A Wedderburn; M Harrison
Journal:  J R Soc Med       Date:  1999-07       Impact factor: 5.344

Review 2.  [Treatment of specific complications of locally advanced prostate cancer].

Authors:  F C von Rundstedt; A S Brandt; D Lazica; M J Mathers; S Roth
Journal:  Urologe A       Date:  2008-11       Impact factor: 0.639

3.  A multidisciplinary approach to the management of hormone-refractory prostate cancer.

Authors:  Samir S Taneja
Journal:  Rev Urol       Date:  2003

4.  A multidisciplinary approach to the management of hormone-refractory prostate cancer.

Authors:  Samir S Taneja
Journal:  Rev Urol       Date:  2003

5.  Flutamide-induced acute renal failure in a patient with metastatic prostate cancer.

Authors:  Mehmet Riza Altiparmak; Ahmet Bilici; Bunyamin Kisacik; Mustafa Ozguroglu
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

Review 6.  Malignant ureteric obstruction decompression: how much gain for how much pain? A narrative review.

Authors:  Joanna Prentice; Tarik Amer; Ali Tasleem; Omar Aboumarzouk
Journal:  J R Soc Med       Date:  2018-04       Impact factor: 5.344

7.  Update in palliative management of hormone refractory cancer of prostate.

Authors:  Pratipal Singh; Aneesh Srivastava
Journal:  Indian J Urol       Date:  2007-01

Review 8.  Role of percutaneous nephrostomy in end of life prostate cancer patients: a systematic review of the literature.

Authors:  Francesca New; Sally Deverill; Bhaskar K Somani
Journal:  Cent European J Urol       Date:  2018-11-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.